Andrew Olaye

Executive Director, Market Access & Partnerships EMEA • Orchard Therapeutics

Andrew Olaye has worked in the Pharmaceutical industry and academic institutes for nearly 20 years, with the last 10 years in companies dedicated to treatment of rare diseases, during which he has contributed to the successful commercialisation of several ATMPs including Libmeldy, Strimvelis and Roctavian as well as several orphan drugs within Europe and the middle east. His current responsibilities at Orchard include coordinating the market access activities and external partnerships in Europe and Middle East

Also Speaking

Dan Strange

Chief Technology Officer • Cellular Origins, A TTP Company

Ian Gaudet

Senior Director, Site Head San Jose • Miltenyi Biotec

Gregory Fiore

Founder and Chief Executive Officer • Exacis Biotherapeutics

Also Speaking


Post-Event Report

Download the post-event report for Advanced Therapies Week 2024.

Investor List

Take a look at some of the investors who attended Advanced Therapies Week 2023.